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Factors related to the development of microalbuminuria in
hypertension are not well known. We did a prospective study to
investigate whether glomerular hyperfiltration precedes the
development of microalbuminuria in hypertension. We
assessed 502 never-treated subjects screened for stage 1
hypertension without microalbuminuria at baseline and
followed up for 7.8 years. Creatinine clearance was measured at
entry. Urinary albumin and ambulatory blood pressure were
measured at entry and during the follow-up until subjects
developed sustained hypertension needing antihypertensive
treatment. Subjects with hyperfiltration (creatinine clearance
4150 ml/min/1.73 m2, top quintile of the distribution) were
younger and heavier than the rest of the group and had a
greater follow-up increase in urinary albumin than subjects with
normal filtration (Po0.001). In multivariable linear regression,
creatinine clearance adjusted for confounders was a strong
independent predictor of final urinary albumin (Po0.001).
In multivariable Cox regression, patients with hyperfiltration
had an adjusted hazard ratio for the development of
microalbuminuria based on at least one positive measurement
of 4.0 (95% confidence interval (CI), 2.1–7.4, Po0.001) and an
adjusted hazard ratio for the development of microalbuminuria
based on two consecutive positive measurements of 4.4 (95%
CI, 2.1–9.2, Po0.001), as compared with patients with normal
filtration. Age, female gender, and 24 h systolic blood pressure
were other significant predictors of microalbuminuria. In
conclusion, stage 1 hypertensive subjects with glomerular
hyperfiltration are at increased risk of developing
microalbuminuria. Early intervention with medical therapy may
be beneficial in these subjects even if their blood pressure falls
below normal limits during follow-up.
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According to the Joint National Committee on Detection,
Evaluation, and Treatment of High Blood Pressure (JNC-7)1
and the European Society of Hypertension/European Society of
Cardiology,2 guidelines for initiating antihypertensive treatment
should be based on two main criteria: the level of systolic and
diastolic blood pressure and the total level of cardiovascular risk.
Microalbuminuria entails a higher incidence of fatal events in
hypertension, and is thus considered an important adjunctive
risk factor, which requires early antihypertensive treatment.3–5
This is why assessment of albumin excretion rate (AER) is
increasing in a risk stratification strategy for hypertensive
patients.6–8 According to early experimental studies, glomerular
hypertension and hyperfiltration are key factors in mediating
progressive renal damage.9 A number of studies suggest that this
model of renal injury may apply to the early diabetic kidney
because hyperfiltration has been shown to predict the
development of microalbuminuria and nephropathy in type I
diabetes mellitus.10–12 This finding has been attributed to poor
glycemic control as hyperfiltration showed a correlation with
hemoglobin A1c.11 Little is known on the time course of AER
in hypertensive subjects and on the factors that favor the
development of microalbuminuria in the early stage of
hypertension. In a group of young adults with mild to moderate
hypertension and treated for the disease, Redon et al. found that
the main factors influencing the occurrence of microalbumin-
uria during antihypertensive treatment were the values of AER
at baseline and the slopes for systolic blood pressure and fasting
glucose.13 No data are available on evolution of AER in
untreated hypertensive subjects. In particular, it is not known if
glomerular hyperfiltration precedes the development of micro-
albuminuria in hypertension. The aim of this study was to
investigate the time course of AER in a cohort of young subjects
screened for stage 1 hypertension and to assess whether
glomerular hyperfiltration influences the development of
microalbuminuria in these individuals.
RESULTS
The clinical characteristics of the subjects divided into
quintiles of creatinine clearance at the baseline are reported
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in Table 1. Female gender was more prevalent in the 1st
quintile than the other quintiles. Body mass index (BMI) and
clinic systolic blood pressure increased with increasing levels
of creatinine clearance, whereas age decreased across the
quintiles. AER tended to increase across the quintiles, but the
between-group differences were of borderline significance.
No differences in family history for hypertension, hyperten-
sion duration, smoking, alcohol use, physical activity habits,
plasma glucose, or lipids were found between the quintiles
(data not shown). The length of follow-up and changes in 24-
h systolic and diastolic blood pressure during the follow-up
were similar in the five groups.
Follow-up data
In the whole group, mean follow-up was 7.873.3 years.
Among the entire cohort, 24-h blood pressure increased by
2.9710.3/2.177.6 mm Hg. Body weight increased by
1.775.4 kg and AER rose from (geometric mean (inter-
quartile range)) 4.6 (2.7–8.5) mg/24 h to 7.8 (4.7–12.2 mg/
24 h). During the follow-up, 244 subjects developed sustained
hypertension and were started on antihypertensive treatment.
Their clinic blood pressure increased from 148.8710.4/
95.474.7 mm Hg at baseline assessment to 155.6710.9/
101.877.2 mm Hg at final visit. In the 258 subjects who
remained untreated, clinic blood pressure fell from
145.0710.4/92.775.0 to 134.578.5/86.675.4 mm Hg.
Baseline creatinine clearance was similar in the two subgroups
(124.6741.8 versus 123.1739.1 ml/min/1.73 m2, P¼NS).
In Figure 1, the log-AER values at baseline and after
follow-up in the subjects divided into quintiles of creatinine
clearance are shown. A significant relationship was found
between creatinine clearance quintile and final AER level
(unadjusted Po0.001, and P adjusted for age, sex, BMI,
baseline AER, and time to final assessment¼ 0.001). Log-
AER was significantly higher in the subjects of the 5th
quintile in comparison with the subjects of the first three
quintiles. Similar trends were present in the subjects divided
by sex. However, the relationship was significant in men
(unadjusted P¼ 0.001, adjusted P¼ 0.005) and did not reach
the level of statistical significance after adjustment for
confounders in women (unadjusted P¼ 0.01, adjusted
P¼NS).
Predictors of final AER
A linear regression analysis was performed among the entire
cohort of patients to identify factors that independently
Table 1 | Baseline characteristics, prevalence of final microalbuminuria, and changes in 24-h blood pressure during follow-up in
the 502 subjects divided according to quintiles of creatinine clearance measured at baseline
Variable 1st Quintile 2nd Quintile 3rd Quintile 4th Quintile 5th Quintile P-value
Creatinine clearance, range (ml/min/1.73 m2) o94 94–114 115–124 125–150 4150 —
Sex, M/F (N) 36/64 77/24 84/16 86/15 81/19 o0.001a
Age (years) 37.477.3 36.077.8 34.177.5 31.278.6 31.279.3 o0.001a
BMI (kg/m2) 23.172.6 24.972.5 25.673.2 26.173.3 27.674.3 o0.001a
Duration of hypertension (months) 40.4748.7 37.6741.5 60.3777.5 38.6756.3 35.7747.9 NS
Clinic systolic BP (mm Hg) 144.9710.0 144.579.7 146.8710.9 148.0711.4 149.779.9 0.001
Clinic diastolic BP (mm Hg) 94.474.2 94.774.5 94.275.3 92.975.7 93.874.9 NS
Mean 24-h systolic BP (mm Hg) 127.6712.3 131.1711.7 129.2710.1 131.079.7 131.7710.9 NS
Mean 24-h diastolic BP (mm Hg) 82.378.4 82.077.8 81.177.5 79.778.0 81.278.0 NS
Albumin excretion rate (mg/24 h)b 4.6 (2.8–8.5) 4.7 (2.4–8.7) 3.7 (2.1–7.6) 5.3 (3.3–9.9) 5.2 (3.2–8.5) 0.058
Creatinine clearance (ml/min/1.73 m2) 82.577.8 102.174.5 116.473.9 135.177.4 183.2746.6 —
Length of follow-up (years) 7.573.5 7.373.5 7.673.4 8.572.8 8.373.1 NS
Total incidence of MA at follow-up (%)c 6.0 4.0 2.0 13.9 20.0 o0.001a
Incidence of persistent MA at follow-up (%)d 2.0 2.0 1.0 5.9 11.0 0.002a
Change in 24-h systolic BP (mm Hg) 2.8710.9 2.7710.2 3.279.4 1.878.8 3.7712.0 NS
Change in 24-h diastolic BP (mm Hg) 1.377.5 2.977.3 2.976.9 2.076.6 1.379.3 NS
BMI, body mass index; BP, blood pressure; F, female; M, male; MA, microalbuminuria.
Data are mean7s.d., unless specified, and are adjusted for age, sex, and BMI.
aUnadjusted.
bGeometric mean (interquartile range) and P-value for log-transformed data.
cMA positive in at least one of two consecutive measurements.
dMA positive in two consecutive measurements.
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Figure 1 | Logarithm of AER at baseline and final assessments in
the 502 subjects divided into quintiles of creatinine clearance at
baseline. Adjusted P-values for final AER are: 5th quintile versus 1st
quintile, P¼ 0.006; 5th quintile versus 2nd quintile, P¼ 0.001; 5th
quintile versus 3rd quintile, P¼ 0.002; 5th quintile versus 4th quintile,
P¼NS.
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influenced the level of AER at final assessment (Table 2).
Independent predictors of final AER were baseline AER,
baseline creatinine clearance, gender (female), age (border-
line significance), and baseline mean 24-h systolic blood
pressure. Time elapsed between baseline and final measure-
ments and changes in 24-h systolic blood pressure during
follow-up were other significant correlates of final AER. The
mean 24-h diastolic blood pressure, clinic systolic blood
pressure, clinic diastolic blood pressure, BMI, lifestyle factors,
triglycerides, total cholesterol, and glucose at baseline, and
changes in mean 24-h diastolic blood pressure, clinic systolic
blood pressure, clinic diastolic blood pressure, body weight,
triglycerides, total cholesterol, and glucose during the follow-
up did not significantly influence the final level of AER.
Subjects with hyperfiltration
When subjects of the top creatinine clearance quintile
(subjects with hyperfiltration, creatinine clearance 4150 ml/
min/1.73 m2) were compared to the rest of the group
(subjects with normal filtration), a higher follow-up increase
in AER adjusted for age, gender, baseline AER, baseline 24-h
blood pressure, change in 24-h blood pressure and follow-up
length (21.5778.8 versus 8.0759.4 mg/24 h, Po0.001), and
a higher adjusted final AER (geometric mean (interquartile
range)¼ 11.6 (5.6–19.5) mg/24 h versus 7.0 (4.3–11.2) mg/
24 h, Po0.001) were observed in the former than the latter.
Microalbuminuria defined on the basis of at least one
positive measurement (n¼ 46) or two consecutive positive
measurements (n¼ 22) was developed more frequently by
the subjects with hyperfiltration than those with normal
filtration (Table 1 and Figure 2). Forty-seven per cent of the
subjects with hyperfiltration versus 54% of the subjects with
normal filtration (NS) did not require antihypertensive
treatment according to current guidelines. To assess the
proportional contribution of covariates to risk of developing
microalbuminuria, a Cox model was fitted including
hyperfiltration, age, gender, AER, and 24-h systolic blood
pressure at baseline as independent variables (Table 3).
Subjects with hyperfiltration had a 300% increase in risk of
developing microalbuminuria in at least one of two
consecutive measurements during the follow-up in compar-
ison with the subjects with normal filtration. Twenty-four-
hour systolic blood pressure at baseline was another
significant modifiable predictor of final microalbuminuria,
whereas change in 24-h systolic blood pressure over time did
not attain the level of statistical significance (P¼ 0.06). Of
note, clinic blood pressure and change in clinic blood
pressure over time did not predict final microalbuminuria in
this model. When time to microalbuminuria positive in two
consecutive measurements was considered as the outcome
Table 2 | Significant predictors of albumin excretion rate at
final assessment: Summary of multiple regression analysis
Variable Estimatea s.e. t-ratio P-value
Log creatinine clearance 0.783 0.161 4.86 o0.001
Log AER, baseline 0.289 0.108 2.69 0.007
Sex (female) 0.328 0.100 3.28 0.001
Age 0.010 0.005 1.90 0.058
24-h SBP, baseline 0.014 0.004 3.19 0.002
24-h SBP change 0.011 0.004 2.43 0.015
Time to final assessment 0.000 0.000 4.52 o0.001
AER, albumin excretion rate; SBP, systolic blood pressure; s.e., standard error.
Multiple R=0.343. Squared multiple R=0.117.
Mean 24-h diastolic blood pressure, clinic systolic blood pressure, clinic diastolic
blood pressure, BMI, lifestyle factors, and metabolic data at baseline, and changes in
mean 24-h diastolic blood pressure, clinic systolic blood pressure, clinic diastolic
blood pressure, body weight, fasting glucose, triglycerides, and total cholesterol
during the follow-up were found to be nonsignificant by the model.
aOf the regression coefficient.
Table 3 | Results of the multivariable Cox regression analysis
including factors predicting development of microalbumi-
nuria (positive in at least one of two measurements) as
categorical variablesa
Factor
Adjusted
hazard ratio 95% CI P-value
Non-modifiable
Age (o35 versus X35 years) 2.7 1.4–5.5 0.004
Sex (female) 2.0 1.0–3.9 0.047
Modifiable
Creatinine clearance o0.001
4150 ml/min/1.73 m2 4.0 2.1–7.4 —
p150 ml/min/1.73 m2 1.0b
24-h Systolic blood pressure 0.005
X130 mm Hg 2.5 1.3–4.9
o130 mm Hg 1.0b — —
CI, confidence interval.
aThe multivariate model was adjusted for albumin excretion rate at baseline.
bThis served as the reference category. Modifiable factors were included as time-
dependent variables.
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Figure 2 | Incidence of microalbuminuria during the follow-up in
the subjects with hyperfiltration (creatinine clearance 4150 ml/
min/1.73 m2, top quintile) and the subjects with normal filtration
(creatinine clearance p150 ml/min/1.73 m2). Microalbuminuria
was defined as an AER X30 mg/24 h in at least one of two
consecutive measurements (total microalbuminuria) or in two
consecutive measurements (persistent microalbuminuria). MA
indicates microalbuminuria.
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variable, the association with hyperfiltration remained
significant (Po0.001) with an adjusted hazard ratio of 4.4
(95% confidence interval (CI), 2.1–9.2).
DISCUSSION
Microalbuminuria is an independent risk factor for cardio-
vascular disease and has been recently proposed as a useful
clinical marker for recognizing hypertensive patients who are
at greater risk for progressive renal failure or cardiovascular
events.3–8,14 However, it is not known whether and to what
extent AER increases in subjects whose blood pressure levels
remain in the borderline hypertensive range and do not fulfill
current criteria for treatment. This issue was explored in the
normoalbuminuric participants of the Hypertension and
Ambulatory Recording VEmetia Study (HARVEST) study,
which enrolls young stage 1 hypertensive subjects never
treated for hypertension. Data were censored subsequent to
any intervention therapy, making this a true natural history
study. The present results show that after a mean follow-up of
about 8 years, in this cohort there was a substantial increase
in AER. During the follow-up, 9.2% of the participants
developed microalbuminuria in at least one of two
consecutive measurements and 4.4% developed persistent
microalbuminuria, and the risk of microalbuminuria was
greater in the presence of hyperfiltration (Figure 2). As we
have no information on creatinine clearance values before
baseline and at the end of the study, we cannot know when
glomerular filtration rate started to increase in our
hyperfilterers and whether hyperfiltration was still present
at the end of the study. However, most of these subjects come
to medical attention when their blood pressure is elevated,
and the present results indicate that detection of hyperfiltra-
tion in this clinical setting is strongly predictive of
development of microalbuminuria.
Several longitudinal studies performed in diabetic subjects
showed that glomerular hyperfiltration in patients with poor
glycemic control precedes the development of microalbumi-
nuria and that in the long run the increased intraglomerular
flow may damage the renal structure.11,15,16 Recently, Amin
et al.17 in a prospective cohort of children with type I diabetes
demonstrated that glomerular hyperfiltration is predictive of
microalbuminuria independent of hemoglobin A1c level. No
longitudinal data are available in non-diabetic samples. In a
cross-sectional analysis of a general population, borderline
and overt microalbuminuria were independently associated
with an elevated glomerular filtration.18 In a cross-sectional
analysis of the HARVEST participants, we showed that
subjects with microalbuminuria have an increase in creati-
nine clearance in comparison with the normoalbuminuric
subjects.19 The above cross-sectional data suggested that the
association between creatinine clearance and renal damage
may follow a parabolic pattern also in non-diabetic subjects
similar to the widely known parabolic or biphasic pattern in
renal function as observed in diabetes.15–17
The present longitudinal results obtained in a cohort of
young normoalbuminuric hypertensive subjects show that
increased creatinine clearance at the baseline was associated
with a higher final adjusted AER level and a more frequent
development of microalbuminuria during the follow-up,
indicating that there is a temporal relationship between
hyperfiltration and microalbuminuria in stage 1 hyperten-
sion. At the baseline, subjects with hyperfiltration had a
similar level of AER compared to the rest of the population.
However, during the 8 years of follow-up microalbuminuria
was developed three times more frequently by the subjects
with hyperfiltration than by those with normal filtration.
The observed relationship between hyperfiltration and
development of microalbuminuria might be explained by
other factors, such as age, gender, obesity, metabolic
abnormalities, and increased 24-h blood pressure load.
Glomerular filtration rate tends to decline with age20,21 and
has been found to be positively related to BMI.22 Indeed, our
subjects in the top creatinine clearance quintile were younger
and heavier than subjects in the other quintiles, and this may
have introduced bias in the presented relation between
baseline creatinine clearance and final albuminuria. However,
even after adjusting for age, gender, BMI, glucose, lipids, 24-h
blood pressure at baseline, and changes in body weight,
metabolic variables, and blood pressure during the follow-up,
the relationship between elevated filtration and development
of microalbuminuria persisted. Longitudinal studies in
treated non-diabetic hypertensive subjects showed that
baseline clinic blood pressure18 or clinic blood pressure
changes over time13 are significant predictors of microalbu-
minuria development. In the present study, blood pressure
was measured with ambulatory monitoring, which is a more
sensitive indicator of the 24-h blood pressure load than is
clinic blood pressure. Our results show that both baseline
24-h blood pressure and ambulatory blood pressure changes
during follow-up influence final AER.
In diabetic subjects, glomerular hyperfiltration is pro-
moted by hyperglycemia.23,24 However, in some studies the
relationship between risk for the development of micro-
albuminuria and glomerular hyperfiltration was found to be
independent of glycemic control.15,17 In the present study of
young hypertensive subjects at low cardiovascular risk,
glomerular filtration rate was unrelated to glycemia and this
may explain why we did not find a significant association
between final AER and metabolic data in the longitudinal
analysis. The stimuli provoking glomerular hyperfiltration
and development of microalbuminuria in the early hyper-
tensive kidney are unclear. An increase in glomerular
capillary pressure and elevation in glomerular filtration rate
might be the consequence of a functional decrease in
nephron number, as shown in several animal and human
models of renal injury.9,25 Increased renal proximal tubule
Naþ reabsorption may occur in essential hypertensive
patients, mostly in obese individuals,26 and a significant role
of increased Naþ reabsorption in the pathophysiology of
glomerular hyperfiltration in hypertension has recently been
described.27 Our subjects with hyperfiltration had increased
BMI compared to the rest of the cohort and obesity has been
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shown to cause glomerular hyperfiltration and preglomerular
vasodilation, which likely exacerbate the effects of increased
arterial pressure to cause renal injury.28
Limitations
Limitations of our study include first that to identify subjects
with hyperfiltration creatinine clearance was used, which
tends to overestimate the real glomerular filtration rate.20
However, our results were obtained in a large homogeneous
sample of subjects without kidney disease. Second, AER
assessment at baseline was repeated only in the participants
with AER415 mg/24 h and, thus, we cannot exclude that
some subjects with baseline AER below that level would
develop microalbuminuria at repeat measurement. Third,
our interval follow-up time of 8 years may have been
inadequate for studying the temporal relationship between
baseline glomerular filtration rate and final microalbumin-
uria. However, in most studies that found an association
between baseline hyperfiltration and development of micro-
albuminuria in diabetic patients, length of follow-up ranged
from 5 to 11 years.12,15,17 Because we included white patients
with mild hypertension younger than 45 years of age, our
results may not be extrapolated to all hypertensive patients
and may not be generalizable to other races or ethnicities.
Finally, we cannot exclude that pathogenetic mechanisms
other than hyperfiltration may lead to microalbuminuria in
hypertension, as suggested by the tendency to a J-shaped
relationship between glomerular filtration rate and AER in
our patients. Indeed, subjects with hyperfiltration were more
frequently male and were younger and heavier than subjects
of the bottom creatinine clearance quintile, suggesting that
the hyperfiltration-related mechanism of microalbuminuria
is more common in men of young age and in obese
individuals.
Clinical implications
According to the Joint National Committee on Detection,
Evaluation, and Treatment of High Blood Pressure (JNC-7)1
or the 2003 European Society of Hypertension/European
Society of Cardiology2 guidelines, in low-risk subjects
screened for stage 1 hypertension, treatment should be
deferred if their blood pressure levels decline to below 140/
90 mm Hg. Those same guidelines acknowledge the im-
portance of microalbuminuria as a cost-effective approach to
the stratification of overall risk in hypertension. The present
data indicate that subjects with stage 1 hypertension and
glomerular hyperfiltration have a high risk of developing
microalbuminuria irrespective of their blood pressure level
and should thus be treated for hypertension even if their
clinic blood pressure declines to within the normal range.
Almost 50% of our subjects with hyperfiltration did not need
antihypertensive treatment according to current guidelines.
Angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers, which are effective in reducing glomerular
hypertension,27 appear as drugs of choice for delaying
the onset of microalbuminuria.29 Aldosterone antagonists,
at least at the level of conjecture, could also have a beneficial
effect in these subjects as these drugs recently proved effective
in reducing glomerular hyperfiltration.30,31 Whether anti-
hypertensive treatment is really beneficial for delaying renal
damage in subjects with glomerular hyperfiltration should be
tested in further studies.
MATERIALS AND METHODS
Study population
The study participants took part in the HARVEST, an observational
study on the predictive value of 24-h ambulatory blood pressure for
the development of sustained hypertension in young, 18–45 years
old, never-treated patients with stage 1 hypertension.32,33 The study
is conducted in 17 Hypertension Units in Italy. In the HARVEST
study, subjects with diastolic blood pressure between 90 and 99 mm
Hg and/or systolic blood pressure between 140 and 159 mm Hg at
baseline examination are enrolled. Baseline blood pressure was the
mean of six readings obtained during two visits performed 2 weeks
apart. Patients with diabetes mellitus, nephropathy, urinary tract
infections, and other relevant cardiovascular risk factors are
excluded.32,33 Ten Hypertension Units opted to measure urinary
albumin and 24-h blood pressure also during the follow-up, and
thus the specific investigation on the time course of AER was carried
out in 593 white subjects for whom AER and 24-h blood pressure
measurements were available both at baseline and final assessments.
Fifty-seven patients in whom creatinine clearance was unavailable
and 34 patients with microalbuminuria at baseline were excluded
leaving a final sample of 502 subjects for analysis. Mean (7s.d.)
office blood pressure at entry in the 502 patients (364 men)
considered in this report was 146.8710.6/94.075.0 mm Hg, their
mean age was 34.078.5 years, and their BMI was 25.573.6 kg/m2.
In the present sample, blood pressure and age were slightly higher
than in the rest of the cohort (145.3710.4/93.375.6 and
33.178.4 mm Hg, respectively; Po0.001 for all), whereas BMI
and sex distribution were similar in the two subgroups. The study
was approved by the HARVEST Ethics Committee, and written
informed consent was given by the participants.
Procedures
The procedures followed were in accordance with institutional
guidelines. The baseline data included a medical and family history
and a questionnaire of current use of alcoholic beverages and
tobacco and physical activity habits.32 All subjects underwent
physical examination, anthropometry, blood chemistry, urine
analysis, office blood pressure and 24-h blood pressure measure-
ments, electocardiogram, and 24-h urine collection for the
measurement of AER. BMI was considered as an index of adiposity
(weight divided by height squared). Creatinine clearance was
computed from creatinine excretion in a 24-h urine collection and
a single measurement of serum creatinine, and the data were
normalized by body surface area. Twenty-four-hour blood pressure
monitoring was performed with Takeda A&D TM2420 model 7
(A&D Co., Tokyo, Japan) or ICR Spacelabs 90207 monitor
(Spacelabs Inc., Redmond, WA, USA). The arithmetic average of
the edited pressure was used as the ambulatory measurement. At
baseline, urine for AER measurement was collected during the 24-h
recordings. AER measurement was repeated within 3 months in all
subjects with AER 415 mg/24 h at first assessment, because an AER
between 15 and 30 mg/24 h can be considered in the high-normal
range.34 Volumes were measured and urine specimens were frozen
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(201C) and sent to the Coordinating Office at the University of
Padova, where the AER level was measured by a commercially
available radioimmunoassay kit (H ALB kit-double antibody, Sclavo
SpA, Cinisello Balsamo, Italy). The lower limit of detection of this
technique is an albumin concentration of 0.5 mg/l. The intra- and
inter-assay variabilities of the method in our laboratory were 4.4
and 6%, respectively.19 The values of AER in a healthy normotensive
population of the same age range and gender (n¼ 98) was (geo-
metric mean (interquartile range)) 5.7 (3.9–8.5) mg/24 h. Subjects
were categorized as having normoalbuminuria (AER¼ 0–29 mg/24 h)
or microalbuminuria (AERX30 mg/24 h). All subjects with micro-
albuminuria at either first or repeat baseline assessment were excluded
from the present analysis (n¼ 34). Other details on the methods
used in the HARVEST study were reported elsewhere.32,33,19
Follow-up
After baseline examination, subjects were given general information
about non-pharmacological measures by the HARVEST investiga-
tors. Follow-up visits were scheduled at 1, 2, 3, and 6 months and
thereafter at 6-month intervals. After each visit, the clinical
investigators transferred all relevant information to the coordinating
center in Padova. Subjects were followed until they developed
sustained hypertension requiring antihypertensive treatment accord-
ing to the guidelines of the British Hypertension Society until 199935
and then of the 1999 World Health Organization/International
Society of Hypertension36 and 2003 European Society of Cardiology/
European Society of Hypertension.2 Ambulatory blood pressure
monitoring and AER assessment were performed at the baseline,
after 3, 5, 8, 10, 13, and 15 years, and/or just before starting
antihypertensive treatment in the patients who developed sustained
hypertension. The last available ambulatory blood pressure
monitoring and AER data were used for the linear multivariable
regression analysis and were defined as final ambulatory blood
pressure and final AER, respectively. Other details on follow-up
procedures were reported elsewhere.32,33
Data analysis
Data are presented as mean7s.d., unless specified. AER was
expressed as geometric mean (interquartile range) in mg/24 h. The
distribution of clinical variables was compared across quintiles of
creatinine clearance using the general linear model procedure and
adjusting for age, sex, and BMI. The significance of differences in
categorical variables was assessed with the w2 test. Differences in final
AER and AER change over time were adjusted also for baseline AER
and time to final assessment. The Tukey–Kramer multiple compari-
sons post hoc test was used for contrasts. Probability values for post
hoc comparisons are provided in Figure 1. To explore the predictors
of evolution of AER, multivariable linear regression analyses were
performed with final AER as dependent variable and risk factors
measured at baseline or their changes from baseline to study end as
the independent variables. Multivariable time-dependent Cox
proportional-hazards analyses were used to regress time until the
development of microalbuminuria against hyperfiltration, including
all variables found to be significant predictors of microalbuminuria
at univariate analysis, using the previously published procedure.19
Hyperfiltration, AER, and ambulatory systolic blood pressure were
entered as time-dependent covariates. Both microalbuminuria
detected in at least one of two consecutive measurements and
microalbuminuria detected in two consecutive measurements were
used as the outcome variable. The mean interval between the
two measurements was 9.475.7 months (range, 3–24 months).
Dichotomous categories of risk factors were incorporated in Cox
models, with the optimal category serving as the referent (Table 3).
Age was divided into two categories above or below the median
value in the group (35 years). Twenty-four-hour systolic blood
pressure was categorized according to whether subjects had normal
(o130 mm Hg) or high (X130 mm Hg) ambulatory 24-h blood
pressure.37 A 5 mm Hg increase in blood pressure was arbitrarily
used as a cutoff point for the follow-up change in 24-h systolic
blood pressure. A two-tailed probability valueo0.05 was considered
significant. For all statistical analyses, AER and creatinine clearance
were logarithmically (base 10) transformed owing to their skewed
distribution. All analyses were performed using Statistica version 6
(Stat Soft Inc., Tulsa, OK, USA). The authors had full access to the
data and take responsibility for its integrity. All authors have read
and agree to the manuscript as written.
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Appendix
List of the HARVEST Centers that enrolled patients for this
study: Cremona – Div. Medica: G Garavelli; Dolo – Div.
Medica: F Pegoraro, S Laurini; Mirano – Cardiologia:
D D’Este; Padova – Clinica Medica 4: F Dorigatti, V Zaetta,
P Frezza, P Bratti, D Perkovic, C Guarnieri; Pordenone –
Centro Cardioreumatologico: G Cignacco, G Zanata; Rover-
eto – Ala – Div. Medica: M Mattarei, T Biasion; Rovigo –
Cardiologia: P Zonzin, A Bortolazzi; San Daniele del Friuli –
Area di Emergenza: L Mos, S Martina, O Vriz; Trento – Div.
Medica: G Devenuto, M Dal Follo; Vittorio Veneto – Div.
Medica: M Santonastaso, E Cozzutti, R Garbelotto, A Mazzer.
Trial coordinator: P Palatini.
584 Kidney International (2006) 70, 578–584
o r i g i n a l a r t i c l e P Palatini et al.: Hyperfiltration and albuminuria in hypertension
